Ingested interferon-alpha prevents allograft islet transplant rejection.

Area of Science:

• Immunology
• Transplantation immunology
• Endocrinology

Background:

• Interferon-alpha (IFN-alpha) acts as a biological response modifier.
• Islet transplantation is a promising alternative to exogenous insulin therapy for diabetes.
• Preventing islet allograft rejection is crucial for successful transplantation.

Purpose of the Study:

• To investigate the efficacy of ingested interferon-alpha (IFN-alpha) in preventing islet allograft rejection.
• To determine if IFN-alpha administration can prolong the survival of transplanted islets.

Main Methods:

• Diabetic C3H mice received islet allografts from C57BL.10 donors.
• Mice were treated with varying doses of ingested murine IFN-alpha daily for 21 to 42 days.
• Graft rejection was monitored by observing blood glucose levels.

Main Results:

• Ingested IFN-alpha significantly delayed islet allograft rejection in a dose-dependent manner.
• Treatment with 10-100 IU of IFN-alpha extended the time to rejection by up to 29 days compared to controls.
• Continuous administration of IFN-alpha for 42 days showed a greater delay in rejection.

Conclusions:

• Prolonged administration of ingested IFN-alpha can prevent islet allograft rejection in a subset of recipients.
• Continuous IFN-alpha treatment post-transplantation holds potential for improving islet allograft survival.
• Ingested IFN-alpha represents a potential therapeutic approach for managing islet transplantation outcomes.